<![CDATA[FENIX CVRMSS Podcast Updates]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.comPowered by Jellypod (https://www.jellypod.com)Sat, 25 Jul 2026 08:45:13 GMTWed, 06 May 2026 18:42:10 GMTyes82e0a282-95d6-4e9a-b797-e15be92b732cFenix Group InternationalDaily briefings on the cardiovascular, renal, and metabolic disease landscape with FENIX's one-of-a-kind insights and implications. Built for biopharma professionals, investors, and analysts who need to stay ahead of the market.Daily briefings on the cardiovascular, renal, and metabolic disease landscape with FENIX's one-of-a-kind insights and implications. Built for biopharma professionals, investors, and analysts who need to stay ahead of the market.episodicFenix Group Internationalfeed+3ce1d1e3@podcasts.jellypod.comfalse<![CDATA[Novo’s Wegovy Pill Receives Approval in EU; Gubra Initiates FIH Study for Muscle-Sparing Asset; GSK Initiates Ph3 Efimosfermin Studies in MASH; Fractyl One Year Data; Ascletis Selects Another FDC in Obesity; Rani Topline Ph1 Data; BI H1 2026 Updates]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/00974d90-5fb4-4297-ab35-7b0f5881e5f400974d90-5fb4-4297-ab35-7b0f5881e5f4Wed, 22 Jul 2026 18:56:20 GMT1111This episode explores the shifting obesity market as oral semaglutide opens the door to broader access, but also exposes the bigger challenge: keeping weight off and preserving muscle after GLP-1s. The conversation weighs peptide-based maintenance bets like Gubra’s GUB-UCN2 against Fractyl’s Revita procedure and other combination strategies racing to solve the post-GLP-1 rebound problem.

]]>Fenix Group InternationalThis episode explores the shifting obesity market as oral semaglutide opens the door to broader access, but also exposes the bigger challenge: keeping weight off and preserving muscle after GLP-1s. The conversation weighs peptide-based maintenance bets liThis episode explores the shifting obesity market as oral semaglutide opens the door to broader access, but also exposes the bigger challenge: keeping weight off and preserving muscle after GLP-1s. The conversation weighs peptide-based maintenance bets like Gubra’s GUB-UCN2 against Fractyl’s Revita procedure and other combination strategies racing to solve the post-GLP-1 rebound problem.false00:07:21full<![CDATA[D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with Calm]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/eaba40c0-ac77-498a-a8de-afe4486a1231eaba40c0-ac77-498a-a8de-afe4486a1231Wed, 22 Jul 2026 18:43:25 GMT1010Pfizer, Dexcom, and Insulet are making very different moves that all point to the same strategy: reduce the daily burden of cardiometabolic care. From oral obesity drugs to longer-wear sensors and mindfulness tools, the episode explores how companies are competing on convenience, adherence, and patient experience.

]]>Fenix Group InternationalPfizer, Dexcom, and Insulet are making very different moves that all point to the same strategy: reduce the daily burden of cardiometabolic care. From oral obesity drugs to longer-wear sensors and mindfulness tools, the episode explores how companies are Pfizer, Dexcom, and Insulet are making very different moves that all point to the same strategy: reduce the daily burden of cardiometabolic care. From oral obesity drugs to longer-wear sensors and mindfulness tools, the episode explores how companies are competing on convenience, adherence, and patient experience.false00:06:33full<![CDATA[Zverev Sports MiniMed at Wimbledon; CSPC/AZ Milestone Payment; Madrigal Rezdiffra Patents; Novo AMAZE 3 Zenagamtide Study]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/d7f72558-7092-4d2a-9050-aa81741c2dacd7f72558-7092-4d2a-9050-aa81741c2dacWed, 15 Jul 2026 17:16:27 GMT99The hosts unpack how Alexander Zverev’s insulin injection at Wimbledon turned chronic disease management into a public, human moment—and why that visibility could be more than just sponsorship theater. They also break down the escalating metabolic-drug race, from AstraZeneca’s CSPC milestones and Novo Nordisk’s expanded obesity pipeline to Madrigal’s patent strategy for Rezdiffra in MASH.

]]>Fenix Group InternationalThe hosts unpack how Alexander Zverev’s insulin injection at Wimbledon turned chronic disease management into a public, human moment—and why that visibility could be more than just sponsorship theater. They also break down the escalating metabolic-drug raThe hosts unpack how Alexander Zverev’s insulin injection at Wimbledon turned chronic disease management into a public, human moment—and why that visibility could be more than just sponsorship theater. They also break down the escalating metabolic-drug race, from AstraZeneca’s CSPC milestones and Novo Nordisk’s expanded obesity pipeline to Madrigal’s patent strategy for Rezdiffra in MASH.false00:08:05full<![CDATA[Novo Initiates NLPR3i Obesity Study; Rani Partners with China-based Biotech Drug Delivery; Pfizer Gets New Head of Obesity Discovery; Novo Sponsors Athletes at Wimbledon]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/f439e61f-46c9-431a-9527-6f953434f106f439e61f-46c9-431a-9527-6f953434f106Wed, 15 Jul 2026 14:48:56 GMT88This episode breaks down Novo Nordisk’s quiet push into an oral NLRP3 inhibitor for obesity and why the company may be betting on inflammation, not just appetite suppression, as the next frontier in metabolic medicine.

It also covers the race to solve delivery, from Rani Therapeutics’ RaniPill partnership with PegBio to the broader push for oral versions of potent GLP-1, dual, and triple agonist therapies.

]]>Fenix Group InternationalThis episode breaks down Novo Nordisk’s quiet push into an oral NLRP3 inhibitor for obesity and why the company may be betting on inflammation, not just appetite suppression, as the next frontier in metabolic medicine. It also covers the race to solve delThis episode breaks down Novo Nordisk’s quiet push into an oral NLRP3 inhibitor for obesity and why the company may be betting on inflammation, not just appetite suppression, as the next frontier in metabolic medicine. It also covers the race to solve delivery, from Rani Therapeutics’ RaniPill partnership with PegBio to the broader push for oral versions of potent GLP-1, dual, and triple agonist therapies.false00:07:01full<![CDATA[Kalohexis Files for US IPO]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/8090de76-2ff5-4a91-8c97-41f572736a188090de76-2ff5-4a91-8c97-41f572736a18Wed, 15 Jul 2026 14:45:15 GMT77Kalohexis is racing to market after spinning out of Endevica Bio, filing for an IPO just months after dosing its first Phase 1 patient with 710GO. We break down its bold bet on the melanocortin pathway, the promise of fat-selective weight loss, and the safety questions that could make or break the company.

]]>Fenix Group InternationalKalohexis is racing to market after spinning out of Endevica Bio, filing for an IPO just months after dosing its first Phase 1 patient with 710GO. We break down its bold bet on the melanocortin pathway, the promise of fat-selective weight loss, and the saKalohexis is racing to market after spinning out of Endevica Bio, filing for an IPO just months after dosing its first Phase 1 patient with 710GO. We break down its bold bet on the melanocortin pathway, the promise of fat-selective weight loss, and the safety questions that could make or break the company.false00:03:37full<![CDATA[Hengrui Ph2 Triple Agonist Study; MindRank Series B; Semaglutide on NEDL; New Foundayo DTC Ad; Endogenex ReCET Enrollment Complete; Ionis/AZ Miss Primary Endpoint in CARDIO-TTRansform; Dr. Reddy’s Halts Sema]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/3f8b227d-13e7-44df-8f47-cb6cce3ed73c3f8b227d-13e7-44df-8f47-cb6cce3ed73cTue, 14 Jul 2026 18:39:33 GMT66We break down the latest triple-agonist weight loss data from Hengrui and Kailera, including the race to prove whether Chinese clinical results can hold up globally. Then we turn to China’s fast-changing oral GLP-1 market, where MindRank, Lilly, Novo, and generic competition are reshaping the commercial playbook.

]]>Fenix Group InternationalWe break down the latest triple-agonist weight loss data from Hengrui and Kailera, including the race to prove whether Chinese clinical results can hold up globally. Then we turn to China’s fast-changing oral GLP-1 market, where MindRank, Lilly, Novo, andWe break down the latest triple-agonist weight loss data from Hengrui and Kailera, including the race to prove whether Chinese clinical results can hold up globally. Then we turn to China’s fast-changing oral GLP-1 market, where MindRank, Lilly, Novo, and generic competition are reshaping the commercial playbook.false00:06:31full<![CDATA[Vivani + Novo Partner for Sema Implant; Kailera Ph3 Oral Obesity and T2DM Data; TIXiMED Ph1b MAD Study; ESC 2026 Hot Line Sessions]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/d3972239-5530-484b-a07a-1ea64fd0a46cd3972239-5530-484b-a07a-1ea64fd0a46cTue, 14 Jul 2026 18:35:57 GMT55We dig into Novo Nordisk’s cautious interest in Vivani’s semaglutide implant and why the idea faces major hurdles in safety, reversibility, and patient acceptance. Then we break down Kailera’s oral GLP-1 Phase 3 results, from modest weight loss to troubling GI side effects, and what they mean for the crowded obesity drug race.

]]>Fenix Group InternationalWe dig into Novo Nordisk’s cautious interest in Vivani’s semaglutide implant and why the idea faces major hurdles in safety, reversibility, and patient acceptance. Then we break down Kailera’s oral GLP-1 Phase 3 results, from modest weight loss to troubliWe dig into Novo Nordisk’s cautious interest in Vivani’s semaglutide implant and why the idea faces major hurdles in safety, reversibility, and patient acceptance. Then we break down Kailera’s oral GLP-1 Phase 3 results, from modest weight loss to troubling GI side effects, and what they mean for the crowded obesity drug race.false00:06:44full<![CDATA[AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany Launch]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/8212c8d1-3438-43f1-af81-b964ab4188f38212c8d1-3438-43f1-af81-b964ab4188f3Tue, 14 Jul 2026 18:22:58 GMT44The hosts unpack AstraZeneca’s latest CSPC siRNA deal for renal disease and what it signals about replacing Farxiga as the cardio-renal market evolves. They also dig into the escalating obesity pipeline race, from ultra-long-acting amylin and GLP-1 combos to retinal imaging in metabolic trials and new titration strategies.

]]>Fenix Group InternationalThe hosts unpack AstraZeneca’s latest CSPC siRNA deal for renal disease and what it signals about replacing Farxiga as the cardio-renal market evolves. They also dig into the escalating obesity pipeline race, from ultra-long-acting amylin and GLP-1 combosThe hosts unpack AstraZeneca’s latest CSPC siRNA deal for renal disease and what it signals about replacing Farxiga as the cardio-renal market evolves. They also dig into the escalating obesity pipeline race, from ultra-long-acting amylin and GLP-1 combos to retinal imaging in metabolic trials and new titration strategies.false00:08:06full<![CDATA[Lilly Ph1b Elora + Tirzep Preliminary Data; Ribo and Madrigal First siRNA Development Milestone; UpDoc FDA Clearance]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/a3772921-8a10-4c78-b88b-04666983227ba3772921-8a10-4c78-b88b-04666983227bTue, 14 Jul 2026 15:47:38 GMT33We break down Eli Lilly’s eye-popping early obesity data, including the tradeoff between dramatic weight loss, tiny sample sizes, and tolerability concerns. The conversation also explores how combination therapies in MASH and FDA-cleared clinical AI could reshape chronic disease management.

]]>Fenix Group InternationalWe break down Eli Lilly’s eye-popping early obesity data, including the tradeoff between dramatic weight loss, tiny sample sizes, and tolerability concerns. The conversation also explores how combination therapies in MASH and FDA-cleared clinical AI couldWe break down Eli Lilly’s eye-popping early obesity data, including the tradeoff between dramatic weight loss, tiny sample sizes, and tolerability concerns. The conversation also explores how combination therapies in MASH and FDA-cleared clinical AI could reshape chronic disease management.false00:07:43full<![CDATA[Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/4549ee0b-6be6-4462-b1be-736059487bce4549ee0b-6be6-4462-b1be-736059487bceTue, 14 Jul 2026 15:31:37 GMT22The hosts break down a major payer move in Massachusetts that drops Dexcom in favor of Abbott’s Libre, showing how reimbursement can reshape market share faster than product launches. They also cover the Medicare GLP-1 Bridge program, booming oral obesity-drug prescriptions, and the race toward new delivery formats like oral dual agonists and semaglutide patches.

]]>Fenix Group InternationalThe hosts break down a major payer move in Massachusetts that drops Dexcom in favor of Abbott’s Libre, showing how reimbursement can reshape market share faster than product launches. They also cover the Medicare GLP-1 Bridge program, booming oral obesityThe hosts break down a major payer move in Massachusetts that drops Dexcom in favor of Abbott’s Libre, showing how reimbursement can reshape market share faster than product launches. They also cover the Medicare GLP-1 Bridge program, booming oral obesity-drug prescriptions, and the race toward new delivery formats like oral dual agonists and semaglutide patches.false00:07:01full<![CDATA[Insulet Appoints Chief R&D Officer; FDA to Review Sandoz Generic Tirzepatide; Kailera Appoints Chief Affairs Officer; Resalis Doses First Patient in Ph1b Obesity Study]]>https://fenix-cvrmss-podcast-upda-gdy2g6.jellypod.com/episodes/e9709b42-be9e-4ccb-ad66-f76a085dbe01e9709b42-be9e-4ccb-ad66-f76a085dbe01Tue, 14 Jul 2026 15:07:27 GMT11This week’s obesity market story spans Insulet’s bold R&D leadership hire, signaling a bigger push in automated insulin delivery, and Sandoz’s generic tirzepatide filing as the market shifts toward volume and price pressure.

The episode also digs into Resalis Therapeutics’ RNA-based RES-010, a potentially game-changing fat-loss asset aimed at preserving muscle and reshaping the next phase of obesity treatment.

]]>Fenix Group InternationalThis week’s obesity market story spans Insulet’s bold R&D leadership hire, signaling a bigger push in automated insulin delivery, and Sandoz’s generic tirzepatide filing as the market shifts toward volume and price pressure. The episode also digs into ResThis week’s obesity market story spans Insulet’s bold R&D leadership hire, signaling a bigger push in automated insulin delivery, and Sandoz’s generic tirzepatide filing as the market shifts toward volume and price pressure. The episode also digs into Resalis Therapeutics’ RNA-based RES-010, a potentially game-changing fat-loss asset aimed at preserving muscle and reshaping the next phase of obesity treatment.false00:06:38full